Free Trial
→ Financial legend: “This is bad, really bad...” (From Weiss Ratings) (Ad)tc pixel
NASDAQ:NBTX

Nanobiotix H1 2026 Earnings Results & Report

Nanobiotix logo
$21.30 -0.93 (-4.18%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$21.37 +0.07 (+0.33%)
As of 10/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nanobiotix was expected to report H1 2026 earnings on September 29, 2026, after market closes. Analysts expected earnings of -$0.4846 per share on revenue of $1.73 million. Confirmed results have not been posted yet. This page will update with the reported figures, conference call transcript, and earnings documents as they become available.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
H1 2026
Announcement Date
Time
After Market Closes
Conference Call Date
Conference Call
4:15 PM ET

Nanobiotix EPS Results

Actual EPS
N/A
Consensus EPS
-$0.4846
Beat/Miss
N/A
One Year Ago EPS
N/A

Nanobiotix Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.73 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Powered by Quartr

Earnings Documents

Nanobiotix's H1 2026 Press ReleasePress Release
Nanobiotix's H1 2026 Interim reportInterim report

Nanobiotix Earnings Headlines

H.C. Wainwright Reaffirms Their Buy Rating on Nanobiotix (0QAV)
October 6, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/NBTX/pressreleases/4930097/hc-wainwright-reaffirms-their-buy-rating-on-nanobiotix-0qav/
Nanobiotix S.A.: NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer
October 2, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-10/69738955-nanobiotix-s-a-nanobiotix-announces-the-appointment-of-arnd-christ-as-chief-financial-officer-399.htm
Financial legend: “This is bad, really bad...”
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
October 18 at 1:00 AM  |  Weiss Ratings (Ad)
Nanobiotix Names Arnd Christ CFO As Rhijn Steps Down
October 2, 2026  |  rttnews.comhttps://www.rttnews.com/3696069/nanobiotix-names-arnd-christ-cfo-as-rhijn-steps-down.aspx
Nanobiotix Appoints Arnd Christ as CFO
October 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/nanobiotix-appoints-arnd-christ-cfo-204615274.html
NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer
October 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/01/3373402/0/en/nanobiotix-announces-the-appointment-of-arnd-christ-as-chief-financial-officer.html
See More Nanobiotix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nanobiotix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nanobiotix and other key companies, straight to your email.

About Nanobiotix

Nanobiotix (NASDAQ:NBTX) is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. Headquartered in France, the company uses its proprietary NanoXray technology to design nanoparticles intended to enhance the effects of radiotherapy within solid tumors.

Nanobiotix’s lead product candidate, NBTXR3, is an investigational radioenhancer composed of hafnium oxide nanoparticles. Administered directly into a tumor before radiotherapy, NBTXR3 is designed to increase energy deposition in cancer cells when exposed to X-rays, with the goal of improving tumor control while using established radiation-treatment techniques.

The company is evaluating NBTXR3 in clinical studies across several cancer indications, including locally advanced soft-tissue sarcoma and head and neck cancers, as well as other solid tumors. Nanobiotix was founded in 2003 and is led by co-founder and Chief Executive Officer Laurent Levy. Its activities are directed toward oncology research and development in the United States, Europe and other international markets.

View Nanobiotix Profile
Earnings Tools